[{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Ecarf Institute GmbH | Bencard Allergie GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"holoBLG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PQGrass306","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PQGrass309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tree MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-based Peanut Allergy Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Allergy Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ Allergy Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Allergy Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : PQGrass306 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 15, 2022

                          Lead Product(s) : PQGrass306

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : VLP Peanut is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 27, 2022

                          Lead Product(s) : VLP Peanut

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : HoloBLG is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypersensitivity.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 13, 2022

                          Lead Product(s) : holoBLG

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Ecarf Institute GmbH | Bencard Allergie GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : VLP Peanut

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : VLP-based Peanut Allergy Vaccine

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Recipient : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : PQGrass309 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 29, 2020

                          Lead Product(s) : PQGrass309

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.

                          Product Name : Grass MATA MPL

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 26, 2020

                          Lead Product(s) : Grass MATA MPL

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergen...

                          Product Name : Tree MATA MPL

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 09, 2020

                          Lead Product(s) : Tree MATA MPL

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Lead Product(s) : Grass MATA MPL

                          Therapeutic Area : Immunology

                          Study Phase : Phase I

                          Sponsor : Syneos Health | Metronomia Clinical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Grass MATA MPL is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 30, 2019

                          Lead Product(s) : Grass MATA MPL

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Syneos Health | Metronomia Clinical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Grass MATA MPL Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          October 21, 2015

                          Lead Product(s) : Grass MATA MPL Extract

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank